ANIP
Ani Pharmaceuticals IncCompany with tickers: ANIP
CIK
1023024
CUSIP
00182C103
Shares Outstanding
22,734,618
13F Activity (30d)
176 filings
171 filers
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 3, 4 and 5. Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Shares |
|---|---|---|---|---|
| 2026-05-13 | Walsh Patrick D |
Director | Sell | 10,000 |
| 2026-05-13 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 |
| 2026-05-12 | Rowland Thomas Andrew |
SVP, HEAD - ESTABLISHED BRANDS | Sell | 459 |
| 2026-05-12 | Gutwerg Ori |
SVP, GENERICS | Sell | 2,772 |
| 2026-05-11 | Walsh Patrick D |
Director | Sell | 3,973 |
| 2026-05-11 | Lalwani Nikhil |
Director, PRESIDENT & CEO | Sell | 55,000 |
| 2026-04-13 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 |
| 2026-03-13 | Mutz Christopher |
HEAD OF RARE DISEASE | Sell | 3,162 |
| 2026-03-13 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. | Sell | 500 |
| 2026-03-11 | Rowland Thomas Andrew |
SVP, HEAD - ESTABLISHED BRANDS | Sell | 4,772 |
| 2026-03-09 | Mutz Christopher |
HEAD OF RARE DISEASE | Sell | 3,602 |
| 2026-03-09 | Davis Krista |
SVP, CHIEF HR OFFICER | Sell | 5,087 |
| 2026-03-07 | Mutz Christopher |
HEAD OF RARE DISEASE | Tax | 3,314 |
| 2026-03-07 | Lalwani Nikhil |
Director, PRESIDENT & CEO | Tax | 17,060 |
| 2026-03-07 | CAREY STEPHEN P. |
SVP & CFO | Tax | 5,150 |
| 2026-03-07 | Gutwerg Ori |
SVP, GENERICS | Tax | 3,314 |
| 2026-03-06 | Davis Krista |
SVP, CHIEF HR OFFICER | Sell | 1,485 |
| 2026-03-06 | Mutz Christopher |
HEAD OF RARE DISEASE | Sell | 2,121 |
| 2026-03-05 | CAREY STEPHEN P. |
SVP & CFO | Convert | 3,312 |
| 2026-03-05 | CAREY STEPHEN P. |
SVP & CFO | Sell | 3,312 |
| 2026-03-05 | CAREY STEPHEN P. |
SVP & CFO | Sell | 4,000 |
| 2026-03-05 | CAREY STEPHEN P. |
SVP & CFO | Convert | 3,312 |
| 2026-03-03 | Gutwerg Ori |
SVP, GENERICS | Sell | 2,060 |
| 2026-03-03 | Walsh Patrick D |
Director | Sell | 6,000 |
| 2026-03-02 | Mutz Christopher |
HEAD OF RARE DISEASE | Sell | 417 |
| 2026-02-28 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. | Tax | 1,555 |
| 2026-02-28 | Rowland Thomas Andrew |
SVP, HEAD - ESTABLISHED BRANDS | Tax | 628 |
| 2026-02-28 | Mutz Christopher |
HEAD OF RARE DISEASE | Tax | 2,221 |
| 2026-02-28 | Gassert Chad |
SVP - CORP. DEV. & STRATEGY | Tax | 2,221 |
| 2026-02-28 | Lalwani Nikhil |
Director, PRESIDENT & CEO | Tax | 12,217 |
| 2026-02-28 | Davis Krista |
SVP, CHIEF HR OFFICER | Tax | 1,555 |
| 2026-02-28 | CAREY STEPHEN P. |
SVP & CFO | Tax | 2,773 |
| 2026-02-28 | Gutwerg Ori |
SVP, GENERICS | Tax | 2,221 |
| 2026-02-26 | Gassert Chad |
SVP - CORP. DEV. & STRATEGY | Other | 158,490 |
| 2026-02-26 | Cook Meredith |
SR. VP, GENERAL COUNSEL & SEC. | Award | 13,895 |
| 2026-02-26 | Shanmugam Muthusamy |
Director, HEAD OF R&D, COO-NOVITIUM OPS | Award | 11,116 |
| 2026-02-26 | Shanmugam Muthusamy |
Director, HEAD OF R&D, COO-NOVITIUM OPS | Other | 431,920 |
| 2026-02-26 | Gassert Chad |
SVP - CORP. DEV. & STRATEGY | Award | 11,116 |
| 2026-02-26 | Shanmugam Muthusamy |
Director, HEAD OF R&D, COO-NOVITIUM OPS | Other | 5,000 |
| 2026-02-26 | CAREY STEPHEN P. |
SVP & CFO | Award | 22,233 |
| 2026-02-26 | Gutwerg Ori |
SVP, GENERICS | Award | 12,969 |
| 2026-02-26 | Davis Krista |
SVP, CHIEF HR OFFICER | Award | 10,810 |
| 2026-02-26 | Rowland Thomas Andrew |
SVP, HEAD - ESTABLISHED BRANDS | Award | 6,021 |
| 2026-02-26 | Lalwani Nikhil |
Director, PRESIDENT & CEO | Award | 75,592 |
| 2026-02-26 | Mutz Christopher |
HEAD OF RARE DISEASE | Award | 21,306 |
| 2026-02-20 | Davis Krista |
SVP, CHIEF HR OFFICER | Sell | 1,730 |
| 2026-02-20 | Mutz Christopher |
HEAD OF RARE DISEASE | Sell | 5,323 |
| 2026-02-19 | Davis Krista |
SVP, CHIEF HR OFFICER | Sell | 2,084 |
| 2026-02-14 | Davis Krista |
SVP, CHIEF HR OFFICER | Tax | 1,290 |
| 2026-02-14 | Rowland Thomas Andrew |
SVP, HEAD - ESTABLISHED BRANDS | Tax | 485 |
Showing 1–50 of 585 transactions